{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-101292","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.880843+00:00","generated_at":"2026-06-03T16:21:53.100319+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024","bullets":["201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.","Plan to initiate a 12-month extension study; requires additional capital.","Pre-IND meeting with FDA for IkT-001Pro in PAH completed; pre-NDA for cancer indications held.","Submitted grants to NINDS/NIH for biomarker development including new monoclonal antibody.","Expects end-of-Phase 2 meeting with FDA by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-101292","json":"https://secwatch.observer/filing/0001193125-24-101292.json","markdown":"https://secwatch.observer/filing/0001193125-24-101292.md","text":"https://secwatch.observer/filing/0001193125-24-101292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/0001193125-24-101292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/d826079d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T16:21:53.100319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}